Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях ...

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов116 Srikantiah P, Walusimbi MN, Kayanja HK et al. Earlyvirological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV andtuberculosis in Uganda. AIDS, 2007, 21(14):1972-1974.117 Davies G, Cerri S, Richeldi L. Rifabutin for treatingpulmonary tuberculosis. Cochrane Database ofSystematic Reviews, 2007, (4):CD005159.118 Li J, Munsiff SS, Driver CR et al. Relapse and acquiredrifampin resistance in HIV-infected patients withtuberculosis treated with rifampin- or rifabutinbasedregimens in New York City, 1997-2000.Clinical Infectious Diseases, 2005, 41(1):83-91.119 CDC. Managing Drug Interactions in the Treatment ofHIV-related Tuberculosis. Rifabutin and Antiretroviraltherapy Atlanta, USA, Centers for Disease Controland Prevention 2009. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/rifabutin_therapy.htm120 Jenny-Avital ER, Joseph K. Rifamycin-resistantMycobacterium tuberculosis in the highly activeantiretroviral therapy era: a report of 3 relapseswith acquired rifampin resistance followingalternate-day rifabutin and boosted proteaseinhibitor therapy. Clinical Infectious Diseases, 2009,48(10):1471-1474.121 WHO. Unedited draft report of the 17th expertcommittee on the selection and use of essentialmedicines. 23 to 27 March 2009. Version: 18 May 2009.Geneva, Switzerland, World Health Organization2009. http://www.who.int/selection_medicines/committees/expert/17/WEBuneditedTRS_2009.pdf122 Blanc FX, Havlir DV, Onyebujoh PC et al. Treatmentstrategies for HIV-infected patients withtuberculosis: ongoing and planned clinical trials.Journal of Infectious Diseases, 2007, 196 Suppl 1:S46-51.123 Abdool Karim SS, Naidoo K, Grobler A et al. Timing ofinitiation of antiretroviral drugs during tuberculosistherapy. New England Journal of Medicine, 2010,362(8):697-706.124 Blanc FXS, T.; Laureillard, D.; Borand, L.; Rekacewicz,C.; Nerrienet, E.; Madec, Y.; Marcy, O.; Chan, S.;Prak, N.; Kim, C.; Lak, K.K.; Hak, C.; Dom, B.; Sin, C.I.;Sun, S.; Guillard, B.; Sar, B.; Vong, S.; Fernandez, M.;Fox, L.; Delfraissy, J.F.; Goldfeld, A.E. . Significantenhancement in survival with early (2 weeks) vs. late(8 weeks) initiation of highly active antiretroivraltreatment (HAART) in severely immunosuppressedHIV-infected adults with newly diagnosed tuberculosis.Vienna, Austria, 2010. http://pag.aids2010.org/Abstracts.aspx?SID=644&AID=17091125 Velasco M, Castilla V, Sanz J et al. Effect ofsimultaneous use of highly active antiretroviraltherapy on survival of HIV patients with tuberculosis.J Acquir Immune Defic Syndr, 2009, 50(2):148-152.126 Westreich D, MacPhail P, Van Rie A et al. Effect ofpulmonary tuberculosis on mortality in patientsreceiving HAART. AIDS, 2009, 23(6):707-715.127 Lawn SD, Bekker LG, Miller RF. Immune reconstitutiondisease associated with mycobacterial infections inHIV-infected individuals receiving antiretrovirals.Lancet Infect Dis, 2005, 5(6):361-373.128 Meintjes G, Lawn SD, Scano F et al. Tuberculosisassociatedimmune reconstitution inflammatorysyndrome: case definitions for use in resourcelimitedsettings. Lancet Infect Dis, 2008, 8(8):516-523.129 Haddow LJ, Moosa MY, Easterbrook PJ. Validationof a published case definition for tuberculosisassociatedimmune reconstitution inflammatorysyndrome. AIDS, 2010, 24(1):103-108.130 Meintjes G, Rangaka MX, Maartens G et al. Novelrelationship between tuberculosis immunereconstitution inflammatory syndrome andantitubercular drug resistance. Clin Infect Dis, 2009,48(5):667-676.131 Meintjes G, Rangaka MX, Maartens G et al. Novelrelationship between tuberculosis immunereconstitution inflammatory syndrome andantitubercular drug resistance. Clinical InfectiousDiseases, 2009, 48(5):667-676.132 Lawn SD, Lipman MC, Easterbrook PJ. Immunereconstitution disease associated withmycobacterial infections. Current Opinion in HIV &AIDS, 2008, 3(4):425-431.43